20 articles
A longevity-linked protein blocks two key mechanisms of doxorubicin heart damage, offering a potential cardioprotective strategy for cancer patients.
Scientists discover targeting two cellular pathways simultaneously could overcome treatment resistance in neuroendocrine tumors.
A Phase 2 trial tests whether a fixed-dose combination pill can safely lower LDL cholesterol in people with type 2 diabetes.
Major study shows tirzepatide reduces cardiovascular and kidney complications by 16% compared to dulaglutide in diabetic patients.
Isoquercitrin reshapes gut bacteria and tryptophan metabolism to reduce arterial plaque, pointing to a novel gut-heart therapeutic pathway.
Sevabertinib demonstrates potential benefits for advanced lung cancer patients with specific genetic mutations.
Revolutionary nanobody drug targets two proteins simultaneously, achieving complete tumor elimination in preclinical studies.
A 2025 review maps the molecular drivers of cardiac aging and evaluates drugs, CRISPR, stem cells, and lifestyle as countermeasures.
Zodasiran shows promise for patients with severe inherited cholesterol disorder, offering hope beyond traditional treatments.
New research reveals how berberine protects the heart in diabetes by activating cellular cleanup of harmful fat accumulation.
New study shows clearing senescent cells with Navitoclax improves heart function and reduces inflammation in heart failure with preserved ejection fraction.
A comprehensive review reveals tirzepatide improves blood pressure, lipids, liver fat, kidney function, and slashes 10-year cardiovascular risk by up to 23.5%.
A Phase 2 trial tests once-daily oral resmetirom (MGL-3196) against placebo to reduce LDL-C in patients with inherited high cholesterol.
Natural isoflavone prevents cardiac enlargement through novel mitochondrial protection pathway, offering new therapeutic approach.
New ACC findings reveal cardiovascular benefits of PCSK9 inhibitors in diabetes patients and tirzepatide's kidney protection effects.
New research shows tirzepatide doesn't surpass dulaglutide's cardiovascular benefits despite being a newer diabetes medication.
Real-world study of 1,559 octogenarians finds SGLT2 inhibitors reduce all-cause death by 42% and heart failure rehospitalization by 31% with no increase in adverse events.
A post hoc analysis of the CLEAR Outcomes trial finds bempedoic acid significantly reduces DVT and pulmonary embolism risk.
Phase 3 trial pits lerodalcibep against inclisiran to determine which PCSK9 inhibitor best cuts LDL in cardiovascular high-risk patients.
Scientists address concerns about sacituzumab govitecan therapy for aggressive triple-negative breast cancer cases.
